Page 48 - 84_02

Differentiation therapy: development of a new drug discovery platform 163

87. Saito Y, Kitamura H, Hijikata A, Tomizawa-
Murasawa M, Tanaka S, Takagi S, et al. Identification
of therapeutic targets for quiescent, chemotherapy-
resistant human leukemia stem cells. Sci Transl Med.
2010 Feb 3;2(17):17ra9.

88. Werbowetski-Ogilvie TE, Bosse M, Stewart M,
Schnerch A, Ramos-Mejia V, Rouleau A, et al.
Characterization of human embryonic stem cells with
features of neoplastic progression. Nat Biotechnol.
2009 Jan;27(1):91-7.

89. Sachlos E, Risueno RM, Laronde S, Shapovalova Z,
Lee JH, Russell J, et al. Identification of drugs
including a dopamine receptor antagonist that
selectively target cancer stem cells. Cell. 2012 Jun
8;149(6):1284-97.

90. Bruserud O, Gjertsen BT. New strategies for the
treatment of acute myelogenous leukemia:
differentiation induction--present use and future
possibilities. Stem Cells. 2000;18(3):157-65.

91. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC,
Wrobel MJ, et al. The Connectivity Map: using gene-
expression signatures to connect small molecules,
genes, and disease. Science. 2006 Sep
29;313(5795):1929-35.

92. Moreno-Martinez D, Nomdedeu M, Lara-Castillo MC,
Etxabe A, Pratcorona M, Tesi N, et al. XIAP
inhibitors induce differentiation and impair clonogenic
capacity of acute myeloid leukemia stem cells.
Oncotarget. 2014 Jun 30;5(12):4337-46.

93. Cornet-Masana JM, Moreno-Martinez D, Lara-
Castillo MC, Nomdedeu M, Etxabe A, Tesi N, et al.
Emetine induces chemosensitivity and reduces
clonogenicity of acute myeloid leukemia cells.
Oncotarget. 2016 Apr 26;7(17):23239-50.

94. Lara-Castillo MC, Cornet-Masana JM, Etxabe A,
Banus-Mulet A, Torrente MA, Nomdedeu M, et al.
Repositioning of bromocriptine for treatment of acute
myeloid leukemia. J Transl Med. 2016 Sep 07;14:261.

95. Etxabe A, Lara-Castillo MC, Cornet-Masana JM,
Banus-Mulet A, Nomdedeu M, Torrente MA, et al.
Inhibition of serotonin receptor type 1 in acute
myeloid leukemia impairs leukemia stem cell
functionality: a promising novel therapeutic target.
Leukemia. 2017 Mar 10.

96. D'Auria FD, Simonetti G, Strippoli V. [Antimicrobial
characteristics of a tincture of dequalinium chloride].
Ann Ig. 1989 Sep-Oct;1(5):1227-41.

97. Della Casa V, Noll H, Gonser S, Grob P, Graf F,
Pohlig G. Antimicrobial activity of dequalinium
chloride against leading germs of vaginal infections.
Arzneimittelforschung. 2002;52(9):699-705.

98. Sukhai MA, Prabha S, Hurren R, Rutledge AC, Lee
AY, Sriskanthadevan S, et al. Lysosomal disruption
preferentially targets acute myeloid leukemia cells and
progenitors. J Clin Invest. 2013 Jan;123(1):315-28.

@Real Academia Nacional de Farmacia. Spain